• Basket
  • Log in

Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

New to Patents? Find out more from CambridgeIP ®

Patents »

US7582733: Humanized antibodies that recognize beta amyloid peptide

Share

Share on Linked In Share on Facebook Share by Email

Filing Information

Inventor(s) Guriq Basi · Jose William Saldanha ·
Assignee(s) Elan Pharma International Limited · Wyeth ·
Attorney/Agent(s) Townsend and Townsend and Crew LLP ·
Primary Examiner Larry R. Helms ·
Assistant Examiner Meera Natarajan ·
Application Number US10232030
Filing date 08/30/2002
Issue date 09/01/2009
Prior Publication Data
Predicted expiration date 11/30/2018
U.S. Classifications 530/387.1  · 530/388.24  ·
International Classifications C07K1600  ·
Kind CodeB2
Related U.S. Application DataRELATED APPLICATIONS
The instant application is a continuation of U.S. patent application Ser. No. 10/010,942, filed Dec. 6, 2001 (granted Mar. 13, 2007 as U.S. Pat. No 7,189,819, which claims the benefit of U.S Provisional Patent Application Ser. No. 60/251,892, filed Dec. 6, 2000 (expired). The entire content of the above-referenced application are incorporated herein by reference.
13 Claims, 10 Drawings


Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

Independent Claims | See all claims (13)

  1. 1. A humanized antibody; which specifically binds to beta amyloid peptide (Aβ) with a binding affinity of at least 107 M−1, or antigen binding fragment thereof selected from the group consisting of a Fab, a Fab′, F(ab′)2, a FV, and a single-chain antibody, wherein the humanized antibody comprises: (i) a humanized light chain comprising three complementarity determining regions (CDR1, CDR2, and CDR3) from the 3D6 immunoglobulin light chain variable region sequence set forth as SEQ ID NO:2, and a light chain variable region framework sequence, wherein at least three framework positions selected from the group consisting of L1, L2, L36, and L46 (Kabat numbering convention) are occupied by Y, V, L and R, respectively, and (ii) a humanized light chain comprising three comnplementarity determining regions (CDR1, CDR2, and CDR3) from the 2D6 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:4, and a heavy chain variable regions framework sequence, wherein framework positions H49, H93, and H94 (Kabat numbering convention) are occupied by A, V, and R respectively.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4666829 University of California Glenner et al. May 1987
US4713366 The Ohio State University Research Foundation Stevens Dec 1987
US4816397* Limited Celltech Boss et al. Mar 1989
US4816567* Genentech, Inc. Cabilly et al. Mar 1989
US4883666 Massachusetts Institute of Technology Sabel et al. Nov 1989
US4912206 The United States of America as represented by the Department of Health and Human Services Goldgaber et al. Mar 1990
US5004697 Univ. of CA Pardridge Apr 1991
US5057540 Cambridge Biotech Corporation Kensil et al. Oct 1991
US5096706 National Research Development Corporation Flint Mar 1992
US5187153 Scios Nova Inc. Cordell et al. Feb 1993
US5192753 MCGEER PATRICK L McGeer et al. Mar 1993
US5208036 Syntex (U.S.A.) Inc. Eppstein et al. May 1993
US5220013 Scios Nova Inc. Ponte et al. Jun 1993
US5225539 Medical Research Council Winter Jul 1993
US5227159 MILLER RICHARD A Miller Jul 1993
US5231000 The McLean Hospital Majocha et al. Jul 1993
US5231170 AVERBACK PAUL Averback Jul 1993
US5245015 Tanox Biosystems, Inc. Fung et al. Sep 1993
US5258498* Creative BioMolecules, Inc. Huston et al. Nov 1993
US5270165 The Reagents of the University of California Van Nostrand et al. Dec 1993
US5278049 Incyte Pharmaceuticals, Inc. Baker et al. Jan 1994
US5385887 Genetics Institute, Inc. Yim et al. Jan 1995
US5387742 Scios Nova Inc. Cordell Feb 1995
US5434170 Andrulis Pharmaceuticals Corp. Andrulis, Jr. Jul 1995
US5441870 Athena Neurosciences, Inc. Seubert et al. Aug 1995
US5464823 The Regents of the University of California Lehrer et al. Nov 1995
US5470951 City of Hope Roberts Nov 1995
US5514548 Morphosys Gesellschaft fur Proteinoptimerung mbH Krebber et al. May 1996
US5530101 Protein Design Labs, Inc. Queen et al. Jun 1996
US5571499 Autoimmune, Inc. Hafler et al. Nov 1996
US5571500 Autoimmune, Inc. Hafler et al. Nov 1996
US5576184 Xoma Corporation Better et al. Nov 1996
US5583112 Cambridge Biotech Corporation Kensil et al. Dec 1996
US5585089 Protein Design Labs, Inc. Queen et al. Dec 1996
US5585100 Henry Jackson Foundation Mond et al. Dec 1996
US5589154 Rutgers, The State University of New Jersey Anderson Dec 1996
US5593846 Athena Neurosciences Schenk et al. Jan 1997
US5601827 President and Fellows of Harvard College Collier et al. Feb 1997
US5605811 Athena Neurosciences, Inc. Seubert et al. Feb 1997
US5612486 Athena Neurosciences, Inc. McConlogue et al. Mar 1997
US5618920* Xoma Corporation Robinson et al. Apr 1997
US5622701 Protein Design Labs, Inc. Berg Apr 1997
US5624821 Scotgen Biopharmaceuticals Incorporated Winter et al. Apr 1997
US5624937 Eli Lilly and Company Reel et al. Apr 1997
US5641473 AutoImmune, Inc. Hafler et al. Jun 1997
US5641474 AutoImmune, Inc. Hafler et al. Jun 1997
US5645820 AutoImmune, Inc. Hafler et al. Jul 1997
US5648260 Scotgen Biopharmaceuticals Incorporated Winter et al. Jul 1997
US5652334 City of Hope Roberts Jul 1997
US5677425 Celltech Therapeutics Limited Bodmer et al. Oct 1997
US5679348 Cedars-Sinai Medical Center Nesburn et al. Oct 1997
US5688651 RAMOT University Authority For Applied Research and Development Ltd. Solomon Nov 1997
US5693761 Protein Design Labs, Inc. Queen et al. Dec 1997
US5693762* Protein Design Labs, Inc. Queen et al. Dec 1997
US5702906 Genentech, Inc. Rosenthal Dec 1997
US5721130 Athena Neurosciences, Inc. Seubert et al. Feb 1998
US5731284 Amgen Inc. Williams Mar 1998
US5733547 AutoImmune, Inc. Weiner et al. Mar 1998
US5733548 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Restifo et al. Mar 1998
US5736142 Cytel Corporation Sette et al. Apr 1998
US5744132 Genetics Institute, Inc. Warne et al. Apr 1998
US5744368 Research Foundation of State University of New York Goldgaber et al. Apr 1998
US5750349 Takeda Chemical Industries Ltd. Suzuki et al. May 1998
US5750361 The Regents of the University of California Prusiner et al. May 1998
US5753624 Milkhaus Laboratory, Inc. McMichael et al. May 1998
US5766846 Athena Neurosciences Schlossmacher et al. Jun 1998
US5770700 Genetics Institute, Inc. Webb et al. Jun 1998
US5776468 SmithKline Beecham Biologicals (S.A.) Hauser et al. Jul 1998
US5780587 President and Fellows of Harvard College Potter Jul 1998
US5786180 Bayer Corporation Konig et al. Jul 1998
US5798102 Milkhaus Laboratory, Inc. McMichael et al. Aug 1998
US5817626 Praecis Pharmaceuticals Incorporated Findeis et al. Oct 1998
US5824322 CytRx Corporation Balasubramanian Oct 1998
US5837268 University of Saskatchewan Potter et al. Nov 1998
US5837672 Athena Neurosciences, Inc. Schenk et al. Nov 1998
US5846533 The Regents of the University of California Prusiner Dec 1998
US5849298 Autoimmune Inc. Weiner et al. Dec 1998
US5851996 Milkhaus Laboratory, Inc. Kline Dec 1998
US5854204 Praecis Pharmaceuticals, Inc. Findeis et al. Dec 1998
US5854215 Praecis Pharmaceuticals Incorporated Findeis et al. Dec 1998
US5858981 UNIV PENNSYLVANIA Schreiber et al. Jan 1999
US5859205 Celltech Limited Adair et al. Jan 1999
US5866129 Tanox Biosystems, Inc. Chang et al. Feb 1999
US5869046 Genentech, Inc. Presta et al. Feb 1999
US5869054 Autoimmune Inc. Weiner et al. Feb 1999
US5869093 Autoimmune Inc. Weiner et al. Feb 1999
US5877399 Johns Hopkins University Hsiao et al. Mar 1999
US5891991 The General Hospital Corporation Wasco et al. Apr 1999
US5935927 The Picower Institute For Medical Research Vitek et al. Aug 1999
US5955079 Henry Jackson Foundation for the Advancement of Military Medicine Mond et al. Sep 1999
US5955317 Takeda Chemical Industries, Ltd. Suzuki et al. Sep 1999
US5958883 Board of Regents of the University of Washington Office of Technology Snow Sep 1999
US5985242 Praecis Pharmaceuticals, Inc. Findeis et al. Nov 1999
US5989566 American Cyanamid Company Cobb et al. Nov 1999
US5994083 Istituto di Recerche di Biologia Molecolare P. Angeletti S.p.A. Felici et al. Nov 1999
US6022859 Wisconsin Alumni Research Foundation Kiessling et al. Feb 2000
US6054297 Genentech, Inc. Carter et al. Apr 2000
US6057367 Duke University Stamler et al. May 2000
US6114133 Elan Pharmaceuticals, Inc. Seubert et al. Sep 2000
US6121022 Genentech, Inc. Presta et al. Sep 2000
US6150091 Baylor College of Medicine Pandolfo et al. Nov 2000
US6165745 Board of Regents, The University of Texas System Ward et al. Dec 2000
US6175057 The Regents of the University of California Mucke et al. Jan 2001
US6180370 Protein Design Labs, Inc. Queen et al. Jan 2001
US6194551 Genentech, Inc. Idusogie et al. Feb 2001
US6210671 Protein Design Labs, Inc. Co Apr 2001
US6218506 Northwestern University Krafft et al. Apr 2001
US6261569 Deakin Research Limited Comis et al. Jul 2001
US6262335 Johns Hopkins University Hsiao et al. Jul 2001
US6267958 Genentech, Inc. Andya et al. Jul 2001
US6270757 Genetics Institute, Inc. Warne Aug 2001
US6277375 Board of Regents, The University of Texas System Ward Aug 2001
US6284221 Elan Pharmaceuticals, Inc. Schenk et al. Sep 2001
US6284533 AVANT Immunotherapeutics, Inc. Thomas Sep 2001
US6294171 Milkhaus Laboratory, Inc. McMichael Sep 2001
US6303567 Praecis Pharmaceuticals, Inc . Findeis et al. Oct 2001
US6331440 Karolinska Innovations AB Nordstedt et al. Dec 2001
US6339068 University of Iowa Research Foundation Krieg et al. Jan 2002
US6372716 Genetics Institute, Inc. Bush et al. Apr 2002
US6399314 American Cyanamid Company Krishnamurthy Jun 2002
US6407213 Genentech, Inc. Carter et al. Jun 2002
US6417178 University of Pittsburgh Klunk et al. Jul 2002
US6528624 Genentech, Inc. Idusogie et al. Mar 2003
US6538124 Genentech, Inc. Idusogie et al. Mar 2003
US6548640 BTG International Limited Winter Apr 2003
US6562341 The Regents of the University of California Prusiner et al. May 2003
US6582945 Boston Biomedical Research Institute Raso Jun 2003
US6610493 Brigham and Womens Hospital Citron et al. Aug 2003
US6632927 Celltech Therapeutics Limited Adair et al. Oct 2003
US6639055 Genentech, Inc. Carter et al. Oct 2003
US6710226 Neuralab Limited Schenk Mar 2004
US6713450 New York University Frangione et al. Mar 2004
US6727349 Millennium Pharmaceuticals, Inc. LaRosa et al. Apr 2004
US6743427 Neuralab Limited Schenk Jun 2004
US6750324* Neuralab Limited Schenk et al. Jun 2004
US6761888 Neuralab Limited Schenk Jul 2004
US6787129 Zenitech LLC Klein et al. Sep 2004
US6787138 Neuralab Limited Schenk Sep 2004
US6787139 Neuralab Limited Schenk Sep 2004
US6787140 Neuralab Limited Schenk Sep 2004
US6787143 Neuralab Limited Schenk Sep 2004
US6787144 Neuralab Limited Schenk Sep 2004
US6787523 Neuralab Limited Schenk Sep 2004
US6787637 Neuralab Limited Schenk et al. Sep 2004
US6808712 Neuralab Limited Schenk Oct 2004
US6818218 Neuralab Limited Schenk Nov 2004
US6866849 Neuralab Limited Schenk Mar 2005
US6866850 Neuralab Limited Schenk Mar 2005
US6875434 Neuralab Limited Schenk Apr 2005
US6890535 Neuralab Limited Schenk May 2005
US6905686 Neuralab Limited Schenk Jun 2005
US6913745 Neuralab Limited Schenk Jul 2005
US6923964 Neuralab Limited Schenk Aug 2005
US6933368 Protein Design Labs, Inc. Co et al. Aug 2005
US6936698 SmithKline Beecham Taylor Aug 2005
US6946135 Neuralab Limited Schenk Sep 2005
US6962707 Neuralab Limited Schenk Nov 2005
US6962984 Nihon University Ishiwata et al. Nov 2005
US6972127 Neuralab Limited Schenk Dec 2005
US6982084 NeuraLab Limited Schenk Jan 2006
US7014855 Neuralab Limited Schenk Mar 2006
US7179819 Daiichi Pharmaceutical Co., Ltd. Basi et al. Feb 2007
US7189819 Wyeth Basi et al. Mar 2007
US7195761 Eli Lilly and Company Holtzman et al. Mar 2007
US20010018053 McMichael Aug 2001
US20010021769 Prusiner Sep 2001
US20020009445 Du et al. Jan 2002
US20020058267 American Home Products Corporation Ozenberger et al. May 2002
US20020077288 New York University Frangione Jun 2002
US20020086847 Mindset Biopharmaceuticals (USA) Chain Jul 2002
US20020094335 Chalifour et al. Jul 2002
US20020102261 Boston Biomedical Research Institute Raso Aug 2002
US20020132268 Chang et al. Sep 2002
US20020133001 Praecis Pharmaceuticals Inc. Gefter et al. Sep 2002
US20020136718 Boston Biomedical Research Institute Raso Sep 2002
US20020160394 Bayer Corporation Wu Oct 2002
US20020162129 Lannfelt Oct 2002
US20020168377 Schaetzl Nov 2002
US20020187157 Jensen et al. Dec 2002
US20020197258 Ghanbari et al. Dec 2002
US20030039645 Adair et al. Feb 2003
US20030068316 Klein et al. Apr 2003
US20030068325 Wang Apr 2003
US20030073655 Chain Apr 2003
US20030092145 Jira et al. May 2003
US20030135035 Shannon Jul 2003
US20030147882 Solomon et al. Aug 2003
US20030165496 Elan Pharmaceuticals, Inc. Basi et al. Sep 2003
US20030166557 Board of Regents, The University of Texas System Minna et al. Sep 2003
US20030166558 NEW YORK UNIVERSITY Frangione et al. Sep 2003
US20030202972 Genentech, Inc. James et al. Oct 2003
US20030207828 Ishiwata et al. Nov 2003
US20040043418 Holtzman et al. Mar 2004
US20040082762 Elan Pharmaceuticals, Inc. Basi et al. Apr 2004
US20040087777 Elan Pharmaceuticals, Inc. Basi et al. May 2004
US20040171815 Schenk et al. Sep 2004
US20040197324 GENENTECH, INC. Jun et al. Oct 2004
US20040241164 Bales et al. Dec 2004
US20040247612 Wang Dec 2004
US20040265919 Vanderstichlele et al. Dec 2004
US20050009150 Elan Pharmaceuticals, Inc. Basi et al. Jan 2005
US20050059591 Neuralab Limited Schenk et al. Mar 2005
US20050059802 Neuralab Ltd Schenk et al. Mar 2005
US20050118651 Neuralab Limited Basi et al. Jun 2005
US20050123534 Celltech R&D Limited Adair et al. Jun 2005
US20050136054 Celltech R&D Limited Adair et al. Jun 2005
US20050152878 Ramot at Tel-Aviv University Ltd. Solomon et al. Jul 2005
US20050163788 Neuralab Limited Schenk Jul 2005
US20050169925 Bardroff et al. Aug 2005
US20050191314 Neuralab Limited Schenk Sep 2005
US20050196399 Schenk et al. Sep 2005
US20050249725 SCHENK DALE B Schenk et al. Nov 2005
US20050249727 Neuralab Limited Schenk Nov 2005
US20050255122 Neuralab Limited Schenk Nov 2005
US20060280743 Neuralab Limited Basi et al. Dec 2006
US20070154480 SCHENK DALE B Schenk et al. Jul 2007
US20070238154 Elan Pharma International Limited Basi et al. Oct 2007
US20080050367 BASI GURIQ Basi et al. Feb 2008

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
AU707083MOURITSEN & ELSNER A SJul 1999
EP285159Oct 1988
EP0391714BRIGHAM & WOMEN'S HOSPITALOct 1990
EP451700Oct 1991
EP276723Dec 1993
EP597101May 1994
EP613007Aug 1994
EP620276Oct 1994
EP626390Nov 1994
EP666080Aug 1995
EP359783Nov 1995
EP683234Nov 1995
EP440619Jan 1996
EP758248Feb 1997
EP758901Feb 1997
EP526511May 1997
EP782859Jul 1997
EP783104Jul 1997
EP594607Aug 1997
EP752886Jan 1998
EP845270Jun 1998
EP863211Sep 1998
EP868918Oct 1998
EP652962Dec 1998
EP911036Apr 1999
EP561087Aug 1999
EP639081Nov 1999
EP506785Mar 2000
EP1172378Dodel, Richard, Dr.Jan 2002
EP1481992WASHINGTON UNIVERSITY ST. LOUISDec 2004
EP1481992WASHINGTON UNIVERSITY ST. LOUISDec 2004
EP921189Jan 2005
GB2220211RIBI IMMUNOCHEM RESEARCH INCJan 1990
GB2335192EXONHIT THERAPEUTICS SASep 1999
JP62267297TOKYO MET GOV SEISHIN IGAKU SOGO KENKYUSHONov 1987
JP7132033May 1995
JP7165799Jun 1995
WO198810120Dec 1988
WO198901343Feb 1989
WO198903687May 1989
WO198906242Jul 1989
WO198906689Jul 1989
WO199012870Nov 1990
WO199012871Nov 1990
WO199108760Jun 1991
WO199109967Jul 1991
WO199112816Sep 1991
WO199116819Nov 1991
WO199116928Nov 1991
WO199119810Dec 1991
WO199206187Apr 1992
WO199206708Apr 1992
WO199213069Aug 1992
WO199222653Dec 1992
WO199302189Feb 1993
WO199304194Mar 1993
WO199314200Jul 1993
WO199315760Aug 1993
WO199316724Sep 1993
WO199321950Nov 1993
WO199400153Jan 1994
WO199401772Jan 1994
WO199403615Feb 1994
WO199405311Mar 1994
WO199409364Apr 1994
WO199410569May 1994
WO199428412Dec 1994
WO199504151Feb 1995
WO199505393Feb 1995
WO199505853Mar 1995
WO199506407Mar 1995
WO199506407Mar 1995
WO199507301Mar 1995
WO199508999Apr 1995
WO199511008Apr 1995
WO199511311Apr 1995
WO199511994May 1995
WO199512815May 1995
WO199517085Jun 1995
WO199523166Aug 1995
WO199523860Sep 1995
WO199531996Nov 1995
WO199608565Mar 1996
WO199618900Jun 1996
WO199625435Aug 1996
WO199628471Sep 1996
WO199637621Nov 1996
WO199639176Dec 1996
WO199703192Jan 1997
WO199708320Mar 1997
WO199710505Mar 1997
WO199717613May 1997
WO199721728Jun 1997
WO199732017Sep 1997
WO199802462Jan 1998
WO199805350Feb 1998
WO199807850Feb 1998
WO199808868Mar 1998
WO199822120May 1998
WO199833815Aug 1998
WO199844955Oct 1998
WO199900150Jan 1999
WO199906066Feb 1999
WO199906587Feb 1999
WO199910008Mar 1999
WO199927911Jun 1999
WO199927944Jun 1999
WO199927949Jun 1999
WO199906545Nov 1999
WO199958564NORSK HYDRO ASANov 1999
WO199960021YEDA RESEARCH AND DEVELOPMENT CO. LTD.Nov 1999
WO199960024THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATIONNov 1999
WO200020027M & E BIOTECH A/SApr 2000
WO200023082YEDA RESEARCH AND DEVELOPMENT CO. LTD.Apr 2000
WO200026238IMPERIAL COLLEGE INNOVATIONS LIMITEDMay 2000
WO200043039DURING, Matthew, JohnJul 2000
WO200043049PHARMACIA & UPJOHN COMPANYJul 2000
WO200068263NEUROCHEM, INC.Nov 2000
WO200072870LTD. NEURALABDec 2000
WO200072876NEURALAB LIMITEDDec 2000
WO200072876NEURALAB LIMITEDDec 2000
WO200072880NEURALAB LIMITEDDec 2000
WO200072880NEURALAB LIMITEDDec 2000
WO200077178BOSTON BIOMEDICAL RESEARCH INSTITUTEDec 2000
WO200105355GENETICS INSTITUTE, INC.Jan 2001
WO200110900UNIVERSITY OF SOUTHERN CALIFORNIAFeb 2001
WO200118169RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD.Mar 2001
WO200139796NEUROCHEM INC.Jun 2001
WO200142306MINDSET BIOPHARMACEUTICALS (USA), INC.Jun 2001
WO200162284PHARMEXA A/SAug 2001
WO200162801WASHINGTON UNIVERSITYAug 2001
WO200162801WASHINGTON UNIVERSITYAug 2001
WO200177167Oct 2001
WO200190182NEW YORK UNIVERSITYNov 2001
WO200203911Lars LANNFELTJan 2002
WO200221141AVENTIS PHARMA S.A.Mar 2002
WO200234777CHIESI FARMACEUTICI S.P.A.May 2002
WO200234878YEDA RESEARCH AND DEVELOPMENT CO. LTD.May 2002
WO200246237NEURALAB LIMITEDJun 2002
WO200246237NEURALAB LIMITEDJun 2002
WO2002060481MILKHAUS LABORATORY, INC.Aug 2002
WO2002088306ELI LILLY AND COMPANYNov 2002
WO2002088307ELI LILLY AND COMPANYNov 2002
WO2002096937NEUROCHEM, INC.Dec 2002
WO2003009817PROTEIN DESIGN LABS, INC.Feb 2003
WO2003015691ELI LILLY AND COMPANYFeb 2003
WO2003016466ELI LILLY AND COMPANYFeb 2003
WO2003016467ELI LILLY AND COMPANYFeb 2003
WO2003016467ELI LILLY AND COMPANYFeb 2003
WO2003020212MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHMar 2003
WO2003039485PROTEIN DESIGN LABSMay 2003
WO2003051374NEW YORK STATE OFFICE OF MENTAL HEALTHJun 2003
WO2003072036DUKE UNIVERSITYSep 2003
WO2003072036DUKE UNIVERSITYSep 2003
WO2003074081MINDSET BIOPHARMACEUTICALS USA INC.Sep 2003
WO2003077858NEURALAB LIMITEDSep 2003
WO2003104437NORTHWESTERN UNIVERSITYDec 2003
WO2003105894MEDIMMUNE, INC.Dec 2003
WO2004013172INNOGENETICS N.V.Feb 2004
WO2004013172INNOGENETICS N.V.Feb 2004
WO2004031400NORTHWESTERN UNIVERSITYApr 2004
WO2004044204INSTITUT PASTEURMay 2004
WO2004044204INSTITUT PASTEURMay 2004
WO2004055164ABGENIX, INC.Jul 2004
WO2004069182NEURALAB LIMITEDAug 2004
WO2004071408APPLIED MOLECULAR EVOLUTION, INC.Aug 2004
WO2004080419NEURALAB LIMITEDSep 2004
WO2004080419NEURALAB LIMITEDSep 2004
WO2004108895NEURALAB LIMITEDDec 2004
WO2004108895NEURALAB LIMITEDDec 2004
WO2005014041NOVARTIS AGFeb 2005
WO2005014041NOVARTIS AGFeb 2005
WO2005026211ELI LILLY AND COMPANYMar 2005
WO2005026211ELI LILLY AND COMPANYMar 2005
* cited by examiner

Other Publications

Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.*
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79:1979-1983).*
Orlandi et al (Proc. Natl. Acad. Sci. USA, 86:3833-3837, 1989).*
Foote et al (J. Foote and G. Winter 1992 J. Mol. Biol. 224:487-499).*
Kettleborough et al (Protein Engineering, 1991, vol. 4: 773-783).*
Colman. Research in Immunology, 145:33-36, 1994.*
Alberts et al. Molecular Biology of the Cell, 3rd ed, pp. 1216-1218, 1994.*
Bendig M. M. Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.*
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.*
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.*
PCT Search Report for application PCT/US04/02856, Neurolab Limited.
PCT Search Report for application PCT/US03/07715, Neurolab Limited et al.
Chen et al., “A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease,” Nature, 408(6815):975-979 (2000).
Janus et al., “A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease,” Nature, 408(6815):979-982 (2000).
Mattson, “Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives,” Physiol Rev., 77(4):1081-132 (1997).
Merluzzi, et al., “Humanized antibodies as potential drugs for therapeutic use,” Adv Clin Path., 4(2):77-85 (2000).
Morgan, et al., “A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease,” Nature, 408(6815):982-985 (2000).
Schenk et al., “Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier,” DNA Cell Biol., 20(11):679-81 (2001).
Selkoe, “The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease,” Trends Cell Biol., 8(11):447-53 (1998).
Sigurdsson, et al., “In vivo reversal of amyloid-beta lesions in rat brain,” J Neuropathol Exp Neurol., 59(1):11-17 (2000).
Sinha, et al., “Recent advances in the understanding of the processing of APP to beta amyloid peptide,” Ann N Y Acad Sci., 920:260-8 (2000).
Soto et al., “Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy,” Nature Medicine., 4(7):822-826 (1998).
Vehmas et al., “beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology,” DNA Cell Biol., (11):713-721 (2001).
Du et al., “Reduced levels of amyloid beta-peptide antibody in Alzheimer's disease,” Neurology, 57(5):801-5 (2001).
Small et al., “Alzheimer's disease and Abeta toxicity: from top to bottom,” Nat Rev Neurosci., 2(8):595-8 (2001).
Masliah et al., “Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer's Disease,” J. Neuroscience, 16(18):5795-5811 (1996).
Irizarry et al., “Aβ Deposition is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse,” J. Neuroscience, 17(18):7053-7059 (1997).
Solomon, B., “Immunological approaches as therapy for Alzheimer's disease,” Expert Opin. Biol. Ther., 2(8):907-917 (2002).
Bard et al., “Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology,” PNAS, 100(4):2023-2028 (2003).
Leverone et al., “Aβ1-15 is less immunogenic than Aβ1-40/42 for intranasal immunization of wild-type mice but may be effective for ‘boosting’,” Vaccine, 21:2197-2206 (2003).
Sigurdsson et al., “Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Trasngenic Mice,” Am. J. Pathology, 159(2):439-447 (2001).
Lemere et al., “Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants,” Neurobiology of Aging, 23(6):991-1000 (2002).
Kettleborough et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation,” Protein Engineering, 4(7):773-783 (1991).
Benjamini et al., from Immunology A Short Course, Second Edition, pp. 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.
Herlyn et al., “Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma,” Eur. J. Immunol., 9:657-659 (1979).
Jahrling et al., “Opsonization of Alphaviruses in Hamsters,” J. Medical Virology, 12:1-16 (1983).
Bellotti et al., “Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosi: Therapeutic Implications,” Renal Failure, 15(3):365-371 (1993).
Frazer et al., “Immunoglobulins: Structure and Function,” chapter 3, pp. 37-74 from Fundamental Immunology, fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).
Chothia et al., “Domain Association in Immunoglobulin Molecules,” J. Mol. Biol., 186:651-663 (1985).
Wu et al., “An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity,” J. Exp. Med., 132:211-250 (1970).
Novotny et al., “Structural invariants of antigen binding: Comparison of immunoglobulin VL-VH and VL-VL domain dimmers,” PNAS, 82:4592-4596 (1985).
Vershigora A. E. Obshchaya Immynologiya, pp. 35, 229-231 and 152-153.
Ziokovic BV, et al., Proc Natl Acad Sci USA., Apr. 30, 1996;93(9):4229-34.
U.S. Appl. No. 60/184,601, filed Feb. 24, 2000, Holtzman, David M. et al.
U.S. Appl. No. 60/254,465, filed Dec. 8, 2000, Holtzman, David M. et al.
U.S. Appl. No. 60/254,498, filed Dec. 8, 2000, Holtzman, David M. et al.
Auld et al, “Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies,” Progress in Neurobiol., 68:209-245 (2002).
Cox et al., “Adjuvants—a classification and review of their modes of action,” Vaccine, 15(3):248-256 (1997).
De Lustig et al., “Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations,” Rev. in Neurosciences, 5:213-225 (1994).
Gupta et al., “Adjuvants for human vaccines—current status, problems, and future prospects,” Vaccine, 13(14):1263-1275 (1995).
Parnetti et al., “Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward,” Drugs, 53(5):752-768 (1997).
Vickers, J.C., “A Vaccine Against Alzheimer's Disease,” Drugs Aging, 19(7):487-494 (2002).
Webster's New World Dictionary of American English, Third College Edition, p. 1078 (1988).
Alberts et al., eds. Molecular Biology of The Cell, Third Edition, chapter 23, pp. 1208-1209 (1994).
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution,” Science, 233:747-753 (1986).
Anderson, J. P., “Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells,” Neuroscience Letters, 128(1):126-128 (1991).
Anderson, M. W., “Amending the amyloid hypothesis,” The Scientist, 18(20):28-29 (2004).
Ankarcrona et al., “Biomarkers for apoptosis in Alzheimer's disease,” Int. J. Geriatric Psychiatry, 20:101-105 (2005).
Bacskai et al., “Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy,” J. Neurosci., 22(18):7873-7878 (2002).
Chimicon International, “Mouse Anti-Amyloid Beta Protein Monoclonal Antibody,” Catalog # MAB1561.
Chromy et al., “Self-assembly of Aβ(1-42) into globular neurotoxins,” Biochemistry, 42(44):12749-12760 (2003).
Citron et al., “Evidence that the 42- and 40- amino acid forms of amyloid-β protein are generated from the β-amyloid precursor protein by different protease activities,” PNAS, 93(23):13170-13175 (1996).
Citron, M., “Alzheimer's disease: treatments in discovery and development,” Nat. Neurosci., 5:1055-1057 (2002).
DeMattos et al., “Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease,” Science, 295(5563):2264-2267 (2002).
Dodart et al., “Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model,” Nat. Neurosci., 5(5):452-457 (2002).
Dodel et al., “Immunotherapy for Alzheimer's disease,” Lancet Neurol., 2(4):215-220 (2003).
Dovey et al., “Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain,” J. Neurochem., 76(1):173-181 (2001).
Duff et al., “Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1,” Nature, 383(6602):710-713 (1996).
Eriksen et al., “NSAIDS and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo,” J. Clin. Invest., 112(3):440-449 (2003).
Findeis, M. A., “Approaches to discovery and characterization of inhibitors and amyloid β-peptide polymerization,” Biochem. Biophys. Acta, 1502(1):76-84 (2000).
Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J. Mol. Biol., 224:487-499 (1992).
Frenkel et al., “Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization,” Vaccine, 21(11-12):1060-1065 (2003).
Frenkel et al., “Towards Alzheimer's β-amyloid vaccination,” Biologicals, 29(3-4):243-247 (2001).
Gelinas et al., “Immunotherapy for Alzheimer's disease,” PNAS, 101(suppl. 2):14657-14662 (2004).
Gong et al., “Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss,” PNAS, 100(18):10417-10422 (2003).
Greenberg et al., “Alzheimer disease's double-edged vaccine,” Nat. Med., 9(4):389-390 (2003).
Haass, C., “New hope for Alzheimer disease vaccine,” Nat. Med., 8(11):1195-1196 (2002).
Hock et al. “Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease,” Nat. Med., 8(11):1270-1275 (2002).
Ida et al., “Analysis of Heterogeneous βA4 Peptides in Juman Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay,” J. Biol. Chem., 271(37):22908-22914 (1996).
Irizarry et al., “Alzheimer disease therapeutics,” J. Neuropathol. Exp. Neurol., 60(10):923-928 (2001).
Janus et al., “Transgenic mouse models of Alzheimer's Disease,” Physiol. Behav., 73(5):873-886 (2001).
Jung et al., “Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study,” J. Neurosci. Res., 46:336-348 (1996).
Kofler et al. “Mechanism of allergic cross-reactions—III. cDNA cloning and variable-region sequence analysis of two IgE antibodies specific for trinitrophenyl.” Mol Immunol. 29(2):161-6 (1992).
Kofler et al. “IgE antibody light chain (VJ) [Mus musculus].” GenBank Accession No. CAA46659. Retrieved from the internet at on Aug. 26, 2005.
Kofler et al. “M.musculus DNA for IgE antibody light chain (VJ).” GenBank Accession No. X65775. Retrieved from the internet at on Aug. 26, 2005.
Krishnan et al., “Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies.” J Immunol. 157(6):2430-9 (1996).
Krishnan et al. “anti-DNA immunoglobulin light chain IgG [Mus musculus].” Genbank Accession No. AAB488000. Retrieved from the internet at on Aug. 26, 2005.
Landolfi et al., “The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody,” J. Immunology, pp. 1748-1754 (2001).
Lo et al., “High level expression and secretion of Fc-X fusion proteins in mammalian cells,” Protein Engineering, 11(6):495-500 (1998).
Mandel et al., “Clinical trials in neurological disorders using AAV vectors: promises and challenges,” Curr. Opin. Mol. Ther., 6(5):482-490 (2004).
Mattson et al., “Good and bad amyloid antibodies,” Science, 301(5641):1845-1849 (2003).
McLaurin et al., “Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis,” Nat Med., 8(11):1263-1269 (2002).
Monsonego et al., “Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease,” J. Clin. Invest., 112(3):415-422 (2003).
Monsonego et al., “Immunotherapeutic approaches to Alzheimer's disease,” Science, 302(5646):834-838 (2003).
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” PNAS, 86:3833-3837 (1989).
Paganetti et al., “Amyloid precursor protein truncated at any of the y-secretase sites is not cleaved to β-amyloid,” J. Neurosci. Res., 46(3):283-293 (1996).
Pallitto et al., “Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity,” Biochemistry, 38(12):3570-3578 (1999).
Panka et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” PNAS, 85:3080-3084 (1998).
Paul, W. E. eds., Fundamental Immunology, Third Edition, pp. 292-295, Raven Press, New York (1993).
Pfeifer et al., “Cerebral hemorrhage after passive anti-Aβ immunotherapy,” Science, 298(5597):1379 (2002).
Racke et al., “Exacerbation of Cerebral Amyloid Angiopathy-Assoiciated Microhemorrhage in Amyloid Precursor Protein Trasngenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β,” J. Neurosci., 25(3):629-636 (2005).
Research Corporation Technology News, “THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs,” Nov. 11, 2002.
“Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice,” downloaded from www.businesswire.com on Dec. 15, 2004.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” PNAS, 79:1979-1983 (1982).
Schmid, R. E., “Study suggest Alzheimer vaccine fix,” from www.msnbc.com/news, pp. 1-5 (2002).
Seidl, K.J. et al. “Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites.” Proc Natl Acad Sci U S A. 96(5):2262-7 (1999).
Seidl, K.J. et al. “immunoglobulin heavy chain VH3609-JH3 region [Mus musculus].” GenBank Accession No. AAD26773. Retrieved from the internet at on Aug. 26, 2005.
Selkoe, D. J., “Alzheimer's disease is a synaptic failure,” Science, 298(5594):789-791 (2002).
Sergeant et al., “Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach,” J. Neurochem., 85(6):1581-1591 (2003).
Sigurdsson et al., “Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice,” Am. J. Pathol., 159(2):439-447 (2001).
Solomon, B., “Generation and brain delivery of anti-aggregating antibodies against β-amyloid plaques using phage display technology,” J. Neural Transm. Suppl., 62:321-325 (2002).
Solomon, B., “Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease,” DNA and Cell Biology, 20(11):697-703 (2001).
Souder et al., “Overview of Alzheimer's disease,” Nurs. Clin. N. Am., 39:545-559 (2004).
Walsh et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo,” Nature, 416(6880):535-539 (2002).
Washington University in St. Louis School of Medicine, “Study gives Clues to Working of Anti-Alzheimer Antibody,” downloaded from www.medicine.wustl.edu/˜wumpa/news on Dec. 15, 2004.
Webster's New World Dictionary, p. 1387, therapeutic (1988).
White et al., “Immunotherapy as a therapeutic treatment for neurodegenerative disorders,” J. Neurochem., 87(4):801-808 (2003).
Clayton et al., “Synucleins in Synaptic Plasticity and Neurodegenerative Disorders,” J. Neurosci. Res., 58:120-129 (1999).
Kuo et al., “Water-soluble Aβ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains,” J. Biol. Chem., 271(8):4077-4081 (1996).
Small et al., “Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease,” PNAS, 97(11):6037-6042 (2000).
Valleix et al., “Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family,” Kidney International, 61:907-912 (2002).
U.S. Appl. No. 11/245,524, filed Oct. 7, 2005, Schenk.
U.S. Appl. No. 11/245,916, filed Oct. 7, 2005, Schenk.
U.S. Appl. No. 60/067,740, filed Dec. 2, 1997, Schenk.
U.S. Appl. No. 60/067,219, filed Dec. 3, 1997, Weiner et al.
U.S. Appl. No. 60/079,697, filed Mar. 27, 1998, Weiner et al.
U.S. Appl. No. 60/080,970, filed Jan. 11, 1999, Schenk.
Alberts et al., Molecular Biology of the Cell, 2nd Edition, pp. 266-267, Garland Publishing Inc., New York (1989).
Auld et al., “Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies,” Progress in Neurobiol., 68:209-245 (2002).
Bales et al., “Administration of an Anti-Aβ Fab Fragment to APPV7 17F Transgenic Mice Reduces Neuritic Plaque,” Abstract P$-396, p. S587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based.
Bickel et al., “Development and in Vitro Characterization of a Cationized Monoclonal Antibody against βA4 Protein: A Potential Probe for Alzheimer's Disease,” Bioconjugate Chem., 5:119-125 (1994).
Blasberg et al., “Regional Localization of Glioma-assoicated Antigen Defined by Monoclonal Antibody 81C6 in Vivo: Kinetics and Implications for Diagnosis and Therapy,” Cancer Research, 47:4432-4443 (1987).
Borenstein, S., “New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans,” Free Press, Jul. 23, 2001.
Brazil et al., “Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia,” J. Biol. Chem., 275(22):16941-16947 (2000).
Broadwell et al, “Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system,” Exp. Neurol., 120(2):245-263 (1993).
Brookmeyer et al., “Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset,” Am. J. Public Health, 88:1337-1342 (1998).
Bussiere et al., “Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive Aβ Immunotherapy on Their Clearance,” Am. J. Pathology, 165(3):987-995 (2004).
Cassell et al., “Demography and Epidemiology of Age-Associated Neuronal Impairment,” chapter 4, pp. 31-50 from Funcitional Neurobiology of Aging, Hof et al., eds., Academic Press (2001).
Clayton et al., “Synucleins in Synaptic Plasticity and Neurodegenerative Disorders,” J. Neurosci. Res., 58:120-129 (1999).
Coico et al., Immunology A Short Course, Fifth Edition, pp. 18-24 (2003).
Das et al., “Reduced effectiveness of Aβ-42 Immunization in APP transgenic mice with significant amyloid deposition,” Neurobiology of Aging, 22:721-727 (2001).
Davis, S. S., “Nasal Vaccines,” Advanced Drug Delivery Reviews, 51:21-42 (2001).
Dewitt et al., “Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease,” Experimental Neurology, 149:329-340 (1998).
Dictionary.com definition of “prophylactic”, pp. 1-3 downloaded from internet Oct. 12, 2005.
Di Martino et al., “Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens,”. J. Molecular Recognition, 4(2-3):85-91 (1991).
Du et al., “α2-Macroglobulin as a β-Amyloid Peptide-Binding Plasma Protein,” J. Neurochemistry, 69(1):299-305 (1997).
European Search Report of May 22, 2006 for European Application 06075704.4-2107.
European Search REport of May 22, 2006 for European Application 06075479.3-2107.
European Search Report of Jan. 16, 2007 for European Application 04776252.1-2405.
Fox et al., “Presymptomatic cognitive deficits in Individuals at risk of familial Alzheimer's disease,” Brain, 121:1631-1639 (1998).
Fukutani et al., “Cerebeller pathology in sporadic and familial Alzheimer's disease including APP 717 (Val→lle) mutation cases: A morphometric investigation,” J. Neurologic Sci., 149:177-184 (1997).
Gupta et al., “Adjuvants for human vaccines—current status, problems, and future prospects,” Vaccine, 13(14):1263-1275 (1995).
Hara et al., “Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease,” J. Alzheimer's Disease, 6:483-488 (2004).
Harlow et al., eds., Antibodies: A Laboratory Manual, pp. 71-82 (1998).
Hirschfield et al., “Amylodiosis: new strategies for treatment,” Int. J. Biochem. & Cell Biol., 35:1608-1613 (2003).
Kajkowski et al., “β-Amytoid Peptide-Induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module,” J. Biol. Chem., 276(22):18748-18756 (2001).
Kalback et al., “APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques,” Biochemistry, 41:922-928 (2002).
Kascsak et al., “Mouse Polyclonal and Monoclonal Antibody to Scraple-Associated Fibril Proteins,” J. Virology, 61(12):3688-3693 (1987).
Klyubin et al., “Anti-Aβ Antibodies Prevent Block of Long-Term Potentiation in the CA1 Area of Rat Hippocampus InVivo by naturally Produced Aβ Oligomers,” Neurobiology of Aging, 25:S224-S225, abstract P2-004, pp. S224-S225 (2004).
Kofler et al., “Immunoglobulin k Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies In Lupus Mice,” J. Clin. Invest., 82:852-860 (1988).
Kuby, J., eds., p. 123 from Immunology, Third Edition, W.H. Freeman & co., (1997).
Kuo et al., “Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains,” J. Biol. Chem., 276(16):12991-12998 (2001).
Kurashima et al., “Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application,” Appl. Pathol., 3(1-2):39-54 (1985).
LaDu et al., “Isoform-specific Binding of Apolipoprotein E to β-Amyloid,” J. Biol. Chem., 269(38):23403-23406 (1994).
Lavie et al., “EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behaviroral Performance in Morris Water Maze Trials,” J. Molecular Neuroscience, 24:105-113 (2004).
Licastro et al., “Is immunotherapy an effective treatment for Alzheimer's disease?,” Immunity & Aging, 1:1-2 (2004).
Linke, “Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis,” J. Histochemistry and Cytochemistry, 32(3):322-328 (1982).
Manoj et al., “Approaches to Enhance the Efficacy of DNA Vaccines,” Critical Rev. Clin. Lab. Sci., 41(1):1-39 (2004).
Marhaug et al., “Monoclonal hybridoma antibodies to human amyloid related protein SAA,” Clin. Exp. Immunol., 50(2):390-396 (1982).
Marotta et al., “Overexpression of amyloid precursor protein A4 (β-amyloid) Immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis,” PNAS, 86:337-341 (1989).
Maury et al., “Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides,” Laboratory Investigation, 64(3):400-404 (1991).
Merriam-Webster online medical dictionary, entry for “cure”, accessed Sep. 5, 2006.
Okie, S., “Promising Vaccine Targets Ravager of Minds,” Washington Post, p. A01, May 8, 2001.
Okura et al., “Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety,” PNAS, 103(25):9619-9624 (2006).
Pardridge et al., “The Blood-Brain Barrier: Bottleneck in Brain Drug Development,” J. Am. Soc. Exp. Neurotherapeutics, 2:3-14 (2005).
PCT Search Report of Aug. 11, 2006 for application PCT/US2006/002837.
PCT Search Report of Aug. 8, 2006 for appl;ication PCT/US2005/045515.
Peeters et al., “Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moleties on the immunogenicity of the conjugates,” J. Immunological Methods, 120:133-143 (1989).
Phelps et al., “Development and Characterization of Monoclonal Antibodies Specific for Amylin,” Hybridoma, 15(5):379-386 (1996).
Press Release, “Alzheimer's vaccine developer awarded Potamkin Prize,” American Academy of Neurology, May 7, 2001.
Probert et al., “Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tunmor necrosis factor α,” PNAS, 92:11294-11298 (1995).
Qu et al., “Aβ42 gene vaccination reduces brain amyloid plaque burden in transgenic mice,” J. Neurological Sciences, 244:151-158 (2006).
Rosenberg, R. N., “The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders,” pp. 1-5.
Saldanha et al., “A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells,” Molecular Immunology, 36:709-719 (1999).
Schenk et al., “Current progress in beta-amyloid immunotherapy,” Curr. Opin. Immunology, 16(5):599-606 (2004).
Shinkai et al., “Amyloid β-Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels,” Ann. Neurol., 38:421-428 (1995).
Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised Jul. 13, 2005.
Travis, J., “A Vaccine for Alzheimer's Disease?®,” Science News Online, 156(2) pp. 1-3 downloaded from internet. (1999).
Trieb et al., “APP Peptides Stimulate Lymphocyte Proliferation In Normals, But Not In Patients With Alzheimer's Disease,” Neurobiology of Aging, 17(4):541-547 (1996).
UniProtKB/Swiss-Prot entry P18525, pp. 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on Feb. 8, 1997, “HV54—Mouse” (Nov. 1, 1990).
Urmoneit et al., “Cerebrovascular Smooth Muscle CElls Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy,” Laboratory Investigation, 77(2):157-166 (1997).
Van Den Dobbelsteen et al., “Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14,” Scand. J. Immunol., 41:273-280 (1995).
Van Leuven, F., “Single and multiple transgenic mice as models for Alzheimer's disease,” Progress in Neurobiology, 61:305-312 (2000).
Vickers, J. C., “A Vaccine Against Alzheimer's Disease,” Drugs Aging, 19(7):487-494 (2002).
Vidanovic et al., “Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation,” Die Pharmazie, 58(6):399-404 (2003).
Wang, W., “Instability, stabilization, and formulation of liquid protein pharmaceuticals,” Int. J. Pharmaceutics, 185(2):129-188 (1999).
Webster's New World Dictionary of American English, Third College Edition, p. 1078 (1988).
Weiner, H. L., “Oral tolerance: Immune mechanisms and treatment of autoimmune diseases,” Immunology Today, 18:335-343 (1997).
Weinreb et al., “NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded,” Biochemistry, 35(43):13709-13715 (1996).
Wikipedia definition of “epitope” printed from internet on Apr. 26, 2006.
Wikipedia definition of “antigen” printed from internet on Apr. 26, 2006.
Wikipedia definition of “route of administration including parenteral” printed from Internet on Apr. 26, 2006.
Yamada et al., “Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A,” Scand. J. Immunol., 46(2):175-179 (1997).
Zameer et al., “Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid-β: Potential therapeutic for Alzheimer's Disease,” Abstract P4-420, p. S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strateles, Amyloid-Based.
Zhang et al., “Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging,” Current Protocols in Mol. Biol., Supp 41, pp. 10.15.1 through 10.15.9 (1998).
Zhang et al., “A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer's disease,” Neurobiology of Disease, 14:365-379 (2003).
U.S. Appl. No. 11/358,951, filed Feb. 22, 2006, Solomon et al.
U.S. Appl. No. 60/251,892, filed Dec. 6, 2000, Basi et al.
U.S. Appl. No. 09/724,842, filed Nov. 28, 2000, Chalifour et al.
U.S. Appl. No. 60/186,295, filed Mar. 1, 2000, Rasmussen et al.
U.S. Appl. No. 60/169,687, filed Dec. 8, 1999, Chain.
U.S. Appl. No. 60/168,594, filed Nov. 29, 1999, Chalifour et al.
U.S. Appl. No. 09/441,140, filed Nov. 16, 1999, Solomon et al.
Aguzzi et al., “Prion research: the next frontiers,” Nature, 389:795-798 (1997).
Aisen, P., “Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Strategies,” Gerontology, 43:143-149 (1997).
Akiyama et al., “Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease,” Glia, 25:324-331 (1999).
Akiyama et al., “Inflammation and Alzheimer's disease,” Neurobiology of Aging, 21:383-421 (2000).
Akiyama et al., “The amino-terminally truncated forms of amyloid β-protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients,” Neuroscience Letters, 219:115-118 (1996).
Andersen et al., “Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?”, Neurology, 45:1441-1445 (1995).
Andrew et al., Current Protocols in Immunology, 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997).
Ard et al., “Scavenging of Alzheimer's Amyloid β-Protein by Microglia in Culture,” J. Neuroscience Research, 43:190-202 (1996).
Arendiash et al., “Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: Task specificity and correlations between Aβ deposition and spatial memory,” DNA and Cell Biology, 20(11):737-744 (2001).
Askelof et al., “Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1,” PNAS, 87:1347-1351 (1990).
Associated Press, “Immune cells may promote Alzehimer's , a study finds,” The Boston Globe (Apr. 13, 1995).
Bacskai et al., “Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy,” Nature Medicine, 7(3):369-372 (2001).
Balbach et al., “Amyloid fibril formation by Aβ16-22, a seven-residue fragment of the Alzheimer's β-amyloid peptide, and structural characterization by solid state NMR,” Biochemistry, 39:13748-13759 (2000).
Bales et al., “Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody,” J. Clin. Invest., 116(3):825-832 (2006).
Bard et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nature Medicine, 6(8):916-919 (2000).
Barrow et al., “Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra,” J. Mol. Biol., 225(4):1075-1093 (1992).
Bauer et al., “Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices,” FEBS Letters, 285(1):111-114 (1991).
Beasley, “Alzheimer's traced to proteins caused by aging,” Reuters, Apr. 20, 2001 7:56 PM ET.
Benjamini et al., from Immunology A Short Course, Second Edition, Chapter 4, Antibody Structure, pp. 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.
Benkirane, et al, “Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues,” J. Biol. Chem., 268(23):26279-26285 (1993).
Ben-Yedidia et al., “Design of peptide and polypeptide vaccines,” Current Opinion in Biotechnology, 8:442-448 (1997).
Bercovici et al., “Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice,” Eur. J. Immunol., 29:345-354 (1999).
Bickel et al., “Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases,” Soc. for Neuroscience Abstracts, 18:764 (1992).
Blass, “Immunologic Treatment of Alzheimer's Disease,” New England J. Medicine, 341(22):1694 (1999).
Bodmer et al., “Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease,” Biochem. Biophys. Res. Comm., 171(2):890-897 (1990).
Borchelt et al., “Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins,” Neuron, 19:939-945 (1997).
Boris-Lawrie et al., “Recent advances in retrovirus vector technology,” Cur. Opin. Genetic Develop., 3:102-109 (1993).
Bork et al., “Go hunting in sequence databases but watch out for the traps,” Trends in Genetics, 12(10):425-427 (1996).
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, 10:398-400 (2000).
Brenner, S. E., “Errors in genome annotation,” Trends in Genetics, 15(4):132-133 (1999).
Brice et al., “Absence of the amyloid precursor protein gene mutation (APP717 : Val->lle) in 85 cases of early onset Alzheimer's disease,” J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).
Britt et al., “Formulation of an immuogenic human cytomegalovirus vaccine: responses in mice,” J. Infect. Dis., 171:18-25 Abstract (1995).
Burdick et al., “Assembly and aggregartion properties of synthetic Alzheimer's A4/β amyloid peptide antigens,” J. Biol. Chem., 267:546-555 (1992).
Cameron, “Recent Advances in Transgenic Technology,” Molecular Biotechnology, 7:253-265 (1997).
Caputo et al., “Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease,” Clin. Neuropharm., 15:414A-414B (1992).
Casadesus et al., “The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease,” Drugs R D, 7(3):187-193 (2006).
Casey, S.O., “Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions,” Amer J Neuroradiol, 21:1199-1206 (2000).
Castillo et al., “Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology,” Diabete & Metabolisme (Paris), 21:3-25 (1995).
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 16, 2002.
Chakrabarti et al., “Vaccinia Virus Expression Vector: Coexpression of B-Galactosidas Provides Visual Screening of Recombinant Virus Plaques,” Molecular and Cellular Biology, 5(12):3403-3409 (1985).
Chang et al., “Adjuvant activity of incomplete Freund's adjuvant,” Advanced Drug Delivery Reviews, 32:173-186 (1998).
Chao et al., “Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury,” Soc. Neurosci. Abstracts, 19:513-7 (1993).
Chapman, “Model behavior,” Nature, 408:915-916 (2000).
Check, “Battle of the Mind,” Nature, 422:370-372 (2003).
Chemical Abstract database, Abstract of “Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals,” Chemical Abstract database. (Publication date unknown.).
Chen et al., “Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice,” Progress in Brain Research, 117:327-337 (1998).
Chen et al., “An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types,” Neuroscience Letters, 125:223-226 (1991).
Chishti et al., “Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695,” J. Biol. Chem., 276(24):21562-70 (2001).
Chung et al., “Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells,” J. Biol. Chem., 274(45):32301-32308 (1999).
Cirrito et al., “Amyloid β and Alzheimer disease therapeutics: the devil may be in the details,” J. Clin. Invest., 112:321-323 (2000).
Co et al., “Chimeric and humanized antibodies with specificity for the CD33 antigen,” J. Immunol., 148:1149-1154 (1992).
Coloma et al., “Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor,” Pharm. Res., 17:266-274 (2000).
Colombian Patent Application No. 98071271, Technical Opinion of Jean Paul Vernot submitted on Jun. 22, 2005 as evidence with the brief amending the nullity action (with English translation) (drafted Nov. 2004).
Comery et al., “Passive Immunization Against β-Amyloid Leads to Acute Cognition Improvement,” Society for Neuroscience, abstract, Washington DC, Nov. 12-16, 2005.
Conway et al., “Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy,” PNAS, 97(2):571-576 (2000).
Cordell, B., “β-Amyloid formation as a potential therapeutic target for Alzheimer's disease,” Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).
Corey-Bloom et al., “Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia,” J. Am. Geriatr. Soc., 41(1):31-37 Abstract (1993).
Costa et al., “Immunoassay for transthyretin variants associated with amyloid neuropathy,” Scand. J. Immunol., 38:177-182 (1993).
Cribbs et al, “All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids,” J. Biol. Chem., 272:7431-7436 (1997).
Daly, et al., “Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain,” Life Sci., 63:2121-2131 (1998).
Das et al., “Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRy Knock-Out-Mice,” J. Neuroscience, 23(24):8532-8538 (2003).
De Felice et al., “β-Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease,” Cell Mol. Neurobiol., 22(5/6):545-563 (2002).
De La Cruz et al, “Immumogenicity [sic] and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage,” J Biol Chem, 263(9):4318-4322 (1988).
Demattos et al., “Peripheral anti-Aβ antibody alters CNS and plasma clearance and decreases Aβ burden in a mouse model of Alzheimer's disease,” PNAS, 98(15):8850-8855 (2001).
Demattos et al., “Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease,” published online before print Jul. 3, 2001 at 10.1073/pnas.151261398; PNAS, 98(15):8850-8855 (2001).
Demattos et al., “Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease,” J. Neurochem., 81:229-236 (2002).
Dialog/Derwent, Abstract of WPI Acc No. 1997-054436/199706: Stable vaccine compsns.—comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database (1997).
Dickey et al., “Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1-42 peptide,” DNA and Cell Biology, 20(11):723-729 (2001).
Dickson et al., “Neuroimmunology of Alzheimer's disease: a conference report,” Neurobiology of Aging, 13(6):793-798 (1992), abstract only.
Diomede et al., “Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes,” Biochem. J., 320:563-570 (1996).
Disis et al., “Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines,” Blood, 88(1):202-210 (1996).
Dodart, “Immunotherapy for Alzheimer's disease: will vaccination work?,” Trends in Molecular Medicine, 9(3):85-87 (2003).
Doerks et al., “Protein annotation: detective work for function prediction,” Trends in Genetics, 14(6):248-250 (1998).
Drew et al., “Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide,” Journal of General Virology, 73:2357-2366 (1992).
Duff et al., “Mouse model made,” Nature, 373:476-477 (1995).
Dumery et al., “β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease,” Pathol. Biol., 49:72-85 (2001).
Eck et al., Goodman and Gilman's The pharmacological basis of therapeutics, Chapter 5, pp. 77-101 (1996).
Ecuador Patent Application No. SP 98-2764, English translation of Expert Report submitted Apr. 19, 2007 in support of the Appeal filed on Jul. 29, 2005.
El-Agnaf et al., “The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide,” Eur. J. Biochem., 256(3):560-569 (1998).
Elan, “Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792,” Press Release. (Jan. 18, 2002).
Elan, “Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration,” Press Release (Mar. 1, 2002).
Elizan et al., “Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease,” J. Neurol. Sciences, 59:341-347 (1983).
Esiri, “Is an effective immune intervention for Alzheimer's disease in prospect?”, Trends in Pharm, Sci., 22:2-3 (2001).
Esler et al., “Point substitution in the central hydrophobic cluster of a human β-amyloid congener disrupts peptide folding and abolishes plaque competence,” Biochemistry, 35:13914-13921 (1996).
European Examination Report of Mar. 9, 2007 for European Application 01995364.5-1222.
European Examination Report of Sep. 26, 2007 for European Application 04720353.4-1222.
European Examination Report of Oct. 8, 2007 for European Application 01995364.5-1222.
Felsenstein et al., “Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation,” Neuroscience Letters, 152:185-189 (1993).
Felsenstein et al., “Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;” Alzheimer's and Parkinson's Diseases, Hanin et al. Ed., pp. 401-409, Plenum Press, New York, (1995).
Finch et al., “Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease,” Neurobiology of Aging, 17(5):809-815 (1996).
Findeis et al, “Modified peptide inhibitors of amyloid B-peptide polymerization,” Biochemistry, 38:6791-6800 (1999).
Fisher et al., “Expression of the amyloid precursor protein gene in mouse oocytes and embryos,” PNAS, 88:1779-1782 (1991).
Flanders et al., “Altered expression of transforming growth factor-β in Alzheimer's disease,” Neurology, 45:1561-1569 (1995).
Flood et al., “An amyloid β-Protein fragment, A β [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures,” Brain Res, 663(2):271-276 (1994).
Flood, et al, “Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid B protein,” PNAS, 91:380-384 (1994).
Fonseca et al., “The Presence of Isoasparatic Acid in β-Amyloid Plaques Indicates Plaque Age,” Experimental Neurology, 157(2):277-288 (1999).
Frautschy et al., “Effects of injected Alzheimer β-amyloid cores in rat brain,” PNAS, 88:8362-8366 (1991).
Frenkel et al., “Generation of auto-antibodies towards Alzheimer's disease vaccination,” Vaccine, 19:2615-2619 (2001).
Frenkel et al., “High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation,” J. of Neuroimmunology, 95:136-142 (1999).
Frenkel et al., “Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration,” PNAS, 97:11455-11459 (2000).
Frenkel et al., “N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies,” J. of Neuroimmunology, 88:85-90 (1998).
Frenkel, et al., “Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody,” J. of Neuroimmunology, 106:23-31 (2000).
Friedland et al., “Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's diseasee,” Mol. Neurology, 9:107-113 (1994).
Friedland, et al., “Neuroimaging of Vessel Amyloid in Alzheimer's Disease,” in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).
Furlan et al., “Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice,” Brain, 126:285-291 (2003).
Games et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein,” Nature, 373(6514):523-527 (1995).
Games et al., “Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with Aβ1−42,” Annals of the New York Academy of Science, 920:274-284 (2000).
Gandy et al., “Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities,” TiPS, 13:108-113 (1992).
Gardella et al., “Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA,” Biochem. Biophys. Res. Comm., 173:1292-1298 (1990).
Gaskin et al., “Human antibodies reactive with beta-amyloid protein in Alzheimer's disease,” J. Exp. Med., 177:1181-1186 (1993).
Geddes, “N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease,” Neurobiology of Aging, 20:75-79 (1999).
Geylis et al., “Immunotherapy of Alzheimer's disease 9AD); From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies,” Autoimmunity Rev., 5:33-39 (2000).
Ghiso et al., “Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease,” Biochem. J., 282 (Pt 2):517-522 (1992).
Gilman, S. et al., “Clinical Effects of AβImmunization (AN1792) in Patients with AD in an Interrupted Trial,” Neurology, 64:1553-1562 (2005).
Giulian et al., “Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia,” J Neurosci., 16 (19):6021-6037 (1996).
Giulian, et al., “The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease,” J. Biol. Chem., 273:29719-29726 (1998).
Glenn et al., “Skin immunization made possible by cholera toxin,” Nature, 391:851 (1998).
Glenner et al., “Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein,” Biochem. Biophys. Res. Comm., 122(3): 1131-1135 (1984).
Glenner et al., “Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein,” Biochem. Biophys. Res. Comm., 120(3): 885-890 (1994).
Goate et al., “Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease,” Nature, 349:704-706 (1991).
Goldfarb et al., “The Transmissible Spongiform Encephalopathies,” Ann. Rev. Med., 46:57-65 (1995).
Goldsby et al., “Vaccines,” Chapter 18 from Immunology, 4th Edition, W.H. Freeman and Company, New York, pp. 449-465 (2000).
Goldsteins et al., “Éxposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants,” PNAS, 96:3108-3113 (1999).
Gonzales-Fernandez et al., “Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation,” Immunology, 93:149-153 (1998).
Gorevic et al., “Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern” Biochem. and Biophy. Res. Commun., 147(2):854-862 (1987).
Gortner, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949).
Gozes et al., “Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide,” PNAS, 93:427-432 (1996).
Gravina et al., “Amyloid β Protein (Aβ) in Alzheimer's Disease,” J. Biol. Chem., 270(13):7013-7016 (1995).
Gross et al., “Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius,” Am J Physiol Regul Integr Comp Physiol, 259:R1131-R1138 (1990).
Grubeck-Loebenstein, et al., “Immunization with β-amyloid: could T-cell activation have a harmful effect?”, TINS, 23:114 (2000).
Gupta et al., “Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs,” Vaccine, 15:(12/13): 1341-1343 (1997).
Haass et al. “Amyloid beta-peptide is produced by cultured cells during normal metabolism,” Nature, 359(6393):322-325 (1992).
Haass et al., “Protofibrils, the unifying toxic molecule of neurodegenerative disorders?,” Nature Neuroscience, 4(9):859-860 (2001).
Haga et al., “Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells,” Brain Research, 601:88-94 (1993).
Hanan and Solomon, “Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation,” Int. J. Exp. Clin. Invest., 3:130-133 (1996).
Hanes et al., “New advances in microsphere-based single-dose vaccines,” Advanced Drug Delivery Reviews, 28: 97-119 (1997).
Hardy, “Amyloid, the presenilins and Alzheimer's disease,” TINS, 20(4): 154-159 (1997).
Hardy, John, “New Insights into the Genetics of Alzheimer's Disease,” Annals of Med., 28:255-258 (1996).
Harigaya, et al., “Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease,” Biochem. Biophys. Res. Comm., 211:1015-1022 (1995).
Harlow et al., eds., Antibodies: A Laboratory Manual, p. 98 (1998).
Harrington et al., “Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein,” Biochimica Biophysica Acta, 1158:120-128 (1993).
Hazama, et al., “Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia coli Heat-Labile Enterotoxin and Interleukin-2,” Immunology, 78:643-649 (1993).
He et al., “Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin,” J. Immunol. 160:1029-1035 (1998).
Helmuth, “Further Progress on a β-Amyloid Vaccine,” Science, 289:375 (2000).
Hilbich et al., “Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease,” J. Mol. Biol., 218:149-163 (1991).
Hilbich et al., “Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease βA4 peptides” J. Mol. Biol., 228:460-473 (1992).
Hilbich et al., “Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4,” Eur. J. Biochem., 201:61-69 (1991).
Hock et al., “Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease,” Neuron, 38:542-554 (2003).
Holtzman et al., “Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer's disease,” Advanced Drug Delivery Reviews, 54:1603-1613 (2002).
Hsiao et al., “Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice,” Science, 274: 99-102 (1996).
Huberman et al., “Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage,” J. Neuroimmunology, 52:147-152 (1994).
Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).
Hyman et al., “Molecular Epidemiology of Alzheimer's Disease,” N. E. J. Medicine, 333(19):1283-1284 (1995).
Idusogie et al., “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc,” J. Immunology, 164:4178-4184 (2000).
Ikeda, et al., “Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody,” Lab. Invest., 57:446-449 (1987).
Itagaki et al., “Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease,” J. Neuroimmunology, 24:173-182 (1989).
Iwatsubo et al., “Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ 42(43),” Neuron, 13:45-53 (1994).
Jakes et al., “Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease,” Alzheimer Disease and Associated Disorders, 9(1):47-51 (1995).
Jansen et al., “Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity,” Immun. Rev., 62: 185-216 (1982).
Jansen et al., “Use of Highly Encapsulated Streptococcus pneumoniae Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specifid Antibodies,” Clinical & Diagnostic Lab. Immunol., 5(5):703-710 (1998).
Jen, et al., “Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein,” Brain Research Protocols, 2:23-30 (1997).
Joachim et al., “Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques,” Am. J. of Pathology, 138:373-384 (1991).
Jobling et al., “Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis,” Molecular Microbiology, 5(7):1755-1767 (1991).
Johnson-Wood et al., “Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease,” PNAS, 94:1550-1555 (1997).
Johnstone et al., Nuclear and Cytoplasmic Localization of the β-Amyloid Peptide (1-43) in Transfected 293 Cells, Biochem. Biophys. Res. Comm., 220:710-718 (1996).
Jorbeck et al., “Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis,” Infection and Immunity, 32(2):497-502 (1981).
Kalaria, R. N., “Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease,” Res. Immunology, 143:637-641 (1992).
Katzav-Gozansky et al., “Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation,” Biotechnol. Appl. Biochem., 23:227-230 (1996).
Kawabata et al., “Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein,” Nature, 354:476-478 (1991).
Kelly, J. W., “Alternative conformations of amyloidogenic proteins govern their behavior,” Current Opinion in Structural Biology, 6:11-17 (1996).
Khatoon et al., “Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains,” FEBS Letters, 351:80-84 (1994).
Kida, et al., “Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain,” Neuroscience Letters, 193:105-108 (1995).
Kimchi et al., “Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy,” J. Neuropath Exp. Neurol., 60(3):274-279 (2001).
Klein et al., “Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?,” Trends in Neurosciences, 24(4):219-224 (2001).
Konig et al., “Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus and the βA4 Peptide,” Annals of NY Acad. Sci., 777:344-355 (1996).
Kotilinek et al., “Reversible memory loss in a mouse transgenic model of Alzheimer's disease,” J. Neurosci., 22(15):6331-6335 (2002).
Koudinov et al., “The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma,” Biochem. & Biophys. Res. Comm, 205:1164-1171 (1994).
Kovács et al., “Mutations of the Prion Protein Gene Phenotypic Spectrum,” J. Neurol., 249:1567-1582 (2002).
Kuby, J., eds., pp. 108-109, 131-132 from Immunology, Third Edition, W.H. Freeman & co., (1997).
Kuo et al., “High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease,” Biochem. Biophys. Res. Comm., 257(3):787-791 (1999).
Lambert et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins,” PNAS, 95:6448-6453 (1998).
Lambert et al., “Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies,” J. Neurochem., 79:595-605 (2001).
Lampert-Etchells et al., “Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease,” Neurodegeneration, 2:111-121 (1993).
Langer, “New Methods of Drug Delivery,” Science, 249:1527-1532 (1990).
Lannfelt et al., “Alzheimer's disease: molecular genetics and transgenic animal models,” Behavioural Brain Res., 57:207-213 (1993).
Lansbury, Peter T., “Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease,” Curr. Ops. in Chemical Biology, 1:260-267 (1997).
Lee et al., “Aβ immunization: Moving Aβ peptide from brain to blood,” PNAS, 98(16):8931-8932 (2001).
Lemere et al., “Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice,” Society for Neuroscience Abstracts, 25(part )I, Abstract 519.6, 29th Annual Meeting, (Oct. 23-28, 1999).
Lemere, et al., “Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice,” Annals of the NY Acad. Sci., 920:328-331 (2000).
Levitt, M., “Molecular dynamics of native protein,” J. Mol . Biol., 168:595-620 (1983).
Levey, A. I., “Immunization for Alzheimer's disease: A shot in the arm or a whiff?,” Ann. Neurology, 48(4):553-555 (2000).
Li et al., “Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu,” Biochem. Mol. Biol. Int., 43(3):601-611 (1997).
Liu et al., “Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis,” Proc. Natl. Acad. Sci., 95:13266-13271 (1998).
Livingston et al., “The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection,” J. Immunol., 159:1383-1392 (1997).
Lopez et al., “Serum auto-antibodies in Alzheimer's disease,” Acta. Neurol. Scand., 84:441-444 (1991).
Lue et al., “Soluble β-amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease,” Am. J. Pathol., 155:853-562 (1999).
Maggio et al., “Brain Amyloid—A Physicochemical Perspective,” Brain Pathology, 6:147-162 (1996).
Majocha et al., “Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy,” The J. of Nuclear Med., 33:2184-2189 (1992).
Mak, et al., “Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum,” Brain Research, 667:138-142 (1994).
Mamikonyan et al., “Anti-Aβ1-11 Antibody Binds to Different β-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers,” J Biol Chem, 282(31)22376-22386 (2007).
Mann, et al., “Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Aβ42(43),” Annals of Neurology, 40:149-156 (1996).
Mann, et al., “The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype,” Neuroscience Letters, 196:105-108 (1995).
Manning et al., “Genetic Immunization with Adeno-Associated Virus Vectors Expressing Herpes Simplex Virus Type 2 Glycoproteins B and D,” Journal of Virology, 71(10):7960-7962 (1997).
Marshall, E., “Gene Therapy's Growing Pains,” Science, 269:1050-1055 (1995).
Masliah et al., “β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease,” PNAS, 98(21):12245-12250 (2001).
Masters et al., “Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome,” PNAS, 82:4245-4249 (1985).
McGee et al., “The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility,” J. Micro. Encap., 14(2):197-210 (1997).
McGeer, et al., “Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy,” J. of Neuroscience Res., 31:428-442 (1992).
McLean et al., “Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease,” Amer. Neurological Assoc, 46:860-866 (1999).
McNeal et al., “Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21,” Virology, 243:158-166 (1998).
Meda et al., “Activation of microglial cells by β-amyloid protein and interferon-γ,” Nature, 374:647-650 (1995).
Mena, et al., “Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease,” Acta Neuropathol., 89:50-56 (1995).
Miller et al., “Antigen-driven Bystander Suppression after Oral Administration of Antigens,” J. Exp. Med., 174:791-798 (1991).
Monsonego et al., “Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease,” PNAS, 98(18):10273-10278 (2001).
Morgan et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRII and FcγRII binding,” Immunology, 86:319-324 (1995).
Mori et al., “Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease,” J. Biol. Chem., 267(24):17082-17088 (1992).
Morris, et al., “The Consortium to Establish a registry for Alzheimer's Disease (CERAD),” Neurology, 39:1159-1165 (1989).
Munch et al., “Potentional neurotoxic inflammatory response to Aβ vaccination in humans,” J. Neural Transm., 109:1081-1087 (2002).
Munson eds., Principals of Pharmacology: Basic Concepts & Clinical Applications, pp. 47-48, Chapman & Hall, New York, New York (1995).
Murphy et al., “Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders,” Am. J. Pathology, 144(5):1082-1088 (1994).
Mutschler et al., Drug Actions: Basic Principles and Therapeutic Aspects pp. 7, 11-12, Medpharm Scientific Publishers, Stuttgart, Germany (1995).
Nakamura et al., “Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys,” Exp. Anim., 43:711-718 (1995).
Nakamura, et al., “Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys,” Neuroscience Letters, 201:151-154 (1995).
Nakayama et al., “Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys,” J. of Med. Primatology, 27:244-252 (1998).
Nalbantoglu, J., “Beta-amyloid protein in Alzheimer's disease,” Can. J. Neurol. Sci., 18(3 suppl.):424-427 (1991), abstract only.
Naslund et al., “Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline,” J. Am. Med. Assoc., 283:1571 (2000).
Nathanson et al., “Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic,” Am. J. Epidemiol., 145(11):959-969 (1997).
New York Times National, “Anti-Inflammatory Drugs May Impede Alzheimer's,” (Feb. 20, 1994).
Newcombe et al., “Solubility characteristics of isolated amyloid fibrils,” Biochim. Biophys. Acta, 104:480-486 (1965).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” pp. 492-495 from Chapter 14 of The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser Boston (1994).
Nicoll et al., “Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report,” Nature Medicine, 9(4):448-452 (2003).
Niemann, “Transgenic farm animals get off the ground,” Transgenic Research, 7:73-75 (1998).
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 7, 1995.
Palha et al., “Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy,” J. Mol. Med., 78:703-707 (2001).
Pan et al., “Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide,” Exp. Biol. Med., 227(8):609-615 (2002).
Pardridge et al., “Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier,” Biochem. Biophys. Res. Comm., 146:307-313 (1987).
Paresce et al., “Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor,” Neuron, 17:553-565 (Sep. 1996).
Paul et al., “Transdermal immunization with large proteins by means of ultradeformable drug carriers,” Eur. J. Immunol., 25:3521-3524 (1995).
PCT International Preliminary Examination Report of Feb. 9, 2004 for application PCT/US01/46587.
PCT Written Opinion of Dec. 14, 2004 for application PCT/US04/02856.
PCT International Preliminary Report on Patentability (Chapter I) of Sep. 16, 2005 with Written Opinion of May 9, 2005 for application PCT/US04/007503.
PCT International Preliminary Report on Patentability (Chapter II) of Apr. 27, 2006 for application PCT/US04/007503.
PCT Search Report of Apr. 6, 2006 and Written Opinion of Apr. 8, 2006 for application PCT/US04/44093.
PCT Search Report of Oct. 1, 2007 and Written Opinion of Oct. 1, 2007 for application PCT/US07/09499.
Perez et al., “The β-Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity,” J. Neurosci., 17(24):9407-9414 (1997).
Persson et al., “IgG subclass-associated affinity differences of specific antibodies in humans,” J. Immunology, 140(11):3875-3879 (1988), abstract only.
Perutz et al., “Amyloid fibers are water-filed nanotubes,” PNAS, 99(8):5591-5595 (2002).
Peterson, et al., “Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies,” Laboratory Animal Science, 46(1):8-14 (1996).
Philippe, et al. “Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein,” J. of Neuroscience Res., 46:709-719 (1996).
Piera et al., “Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn),” Int. J. Cancer, 55(1):148-152 (1993).
Pluckthun, A., “Mono- and Bivalent Antibody Fragments Produced in Escherichia coli: Engineering, Folding and Antigen Binding,” Immunological Reviews, 130:151-188 (1992).
Poduslo et al., “Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease,” Neurobiol. Dis., 8(4):555-567 (2001).
Prieels et al., “Synergistic adjuvants for vaccines,” Chemical Abstracts, 120(8):652, col. 1, abstract 86406t (1994).
Prusiner et al., “Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies,” PNAS, 90:10608-10612 (1993).
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” PNAS, 86:10029-10033 (1989).
Quon et al., “Formation of β-Amyloid protein deposits in brains of transgenic mice,” Nature, 352:239-241 (1991).
Ragusi et al., “Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies,” J. Neurochem., 70(5):2099-2105 (1998).
Rammensee, H.G., “Chemistry of peptides associated with MHC class I and class II molecules,” Current Opinion in Immunology, 7:85-96 (1995).
Raso, “Immunotherapy of Alzheimer's Disease,” Immunotherapy Weekly, Abstract (Apr. 2, 1998).
Raso, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), “Immunotherapy of Alzheimer's Disease” (publication date unknown).
Raso, V.A., Grant application # 1 R43 AGI 5746-01 (redacted version), “Immunotherapy of Alzheimer's Disease” (publication date unknown).
Rodriguez et al., “Enfermedad de Azlheimer. Situacion Actual y Estrategias Terapeuticas” (Alzheimer Disease: present situation and therapeutic strategies), Rev Cubana Med [online], 38(2):134-142 (1999).
Rogers et al., “Complement activation by β-amyloid in Alzheimer Disease,” PNAS, 89:1-5 (1992).
Roses, A.D., “Apoplipoprotein E alleles as risk factors in Alzheimer's disease,” Annu. Rev. Med., 47:387-400 (1996).
Rossor et al., “Alzheimer's Disease Families with Amyloid Precursor Protein Mutations,” Annals of New York Academy of Sciences, 695:198-202 (1993).
Rudinger, “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence,” in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp. 1-7 (1976).
Saido et al., “Spatial Resolution of Fodrin Proteolysis in Postischemic Brain,” J. Biol. Chem., 268(33):25239-25243 (1993).
Saido et al., “Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus,” J. Biol. Chem., 269(21):15253-15257 (1994).
Saito et al., “Vector-mediated delivery of 125l-labeled β-amyloid peptide Ab1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ1-40 vector complex,” PNAS, 92:10227-10231 (1995).
Saitoh, N. et al., “Immunological analysis of Alzheimer's disease using anti- β-protein monoclonal antibodies,” Sapporo Med. J., 60:309-320 (1991).
Sasaki et al., “Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study,” Brain Res., 755:193-201 (1997).
Schenk et al., “Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse,” Nature, 400:173-177 (1999).
Schenk et al., “Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease,” J. Med. Chem., 38(21):4141-4154 (1995).
Schenk et al., “β-peptide immunization,” Arch. Neurol., 57:934-936 (2000).
Schenk, D., “Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning,” Nature Reviews, 3:824-828 (2002).
Schwarzman et al., “Transthyretin sequesters amyloid β protein and prevents amyloid formation,” PNAS, 91:8368-8372 (1994).
Sela et al, “Different roles of D-amino acids in immune phenomena,” FASEB J, 11(6):449-456 (1999).
Selkoe, “Alzheimer's Disease: A Central Role for Amyloid,” J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994).
Selkoe, “Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease,” Trends in Neurosciences, 16(10): 403-409 (1993).
Selkoe, D.J., “Imaging Alzheimer's Amyloid,” Nat. Biotech., 18:823-824 (2000).
Selkoe, Dennis J., “Alzheimer's Disease: Genotypes, Phenotype, and Treatments,” Science, 275:630-631 (1997).
Selkoe, Dennis J., “Amyloid Protein and Alzheimer's Disease . . . ,” Scientific American, pp. 68-78 (1991).
Selkoe, Dennis J., “In the Beginning . . . ,” Nature, 354:432-433 (1991).
Selkoe, Dennis J., “The Molecular pathology of Alzheimer's Disease,” Neuron, 6:487-498 (1991).
Seubert et al., “Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids,” Nature, 359: 325-327 (1992).
Seubert et al., “Antibody Capture of Soluble Aβ does not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse,” Neurodegenerative Diseases, 5:65-71 (2008).
Shiosaka, S., “Attempts to make models for Alzheimer's disease,” Neuroscience Res., 13:237-255 (1992).
Sigmund, “Viewpoint: Are Studies in Genetically Altered Mice Out of Control,” Arterioscler Thromb Vasc Biol., 20:1425-1429 (2000).
Sigurdsson et al., “A safer vaccine for Alzheimer's disease?,” Neurobiology of Aging, 23:1001-1008 (2002).
Sigurdsson et al., “Anti-prion antibodies for prophylaxis following prion exposure in mice,” Neurosciences Letters, 336:185-187 (2003).
Sigurdsson et al., “Immunization Delays the Onset of Prion Disease in Mice,” American Journal of Pathology, 161:13-17 (2002).
Simmons, L., “Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro,” Molecular Pharmacology, 45:373-379 (1994).
Singh, K. S., “Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease,” Gerontology, 43:79-94 (1997).
Singh, V. K., “Studies of neuroimmune markers in Alzheimer's disease,” Mol. Neurobiology, 9(1-3):73-81 (1994), abstract only.
Sipe, “Amyloidosis,” Annu. Rev. Biochem., 61:947-975 (1992).
Skolnick and Fetrow, “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotech, 18(1):34-39 (2000).
Smith et al., “The challenges of genome sequence annotation of ‘The devil is in the details,’” Nature Biotechnology, 15:1222-1223 (1997).
Smits et al., “Prion Protein and Scrapie Susceptibility,” Vet. Quart., 19(3):101-105 (1997).
Solomon and et al., “Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols,” Adv. Mol. Cell Biology, 15A:33-45 (1996).
Solomon et al., “Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens,” Immunotechnology, 2(4):305 (1996).
Solomon et al., “Disaggregation of Alzheimer β-amyloid by site-directed mAb,” PNAS, 94:4109-4112 (1997).
Solomon et al., “Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide,” PNAS, 93:452-455 (1996).
Solomon et al., “The Amino Terminus of the β-Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility,” from Progress in Alzheimer's and Parkinson's Diseases, edited by Fisher et al., Plenum Press, New York, pp. 205-211 (1995).
Solomon, A., “Pro-Rx (Protein Therapeutics),” University of Tennessee Medical Center (publication date unknown).
Solomon, B., “New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response,” Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown).
Solomon et al., “Fast induction of anti-β-amyloid peptide immune response,” Research and Practice in Alzheimer's Disease, 6:260-264 (2002).
Soto et al., “The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation,” J. Biol. Chem, 270(7):3063-3067 (1995).
Soto et al., “The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis,” Biochem. J., 314:701-707 (1996).
Southwick et al., “Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease,” J. Neurochemistry, 66:259-265 (1996).
Spellerberg et al., “DNA Vaccines Against Lymphoma,” Journal of Immunology, 159:1885-1892 (1997).
Spooner et al., “The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol,” Vaccine, 21:290-297 (2002).
St. George-Hyslop et al., “Antibody clears senile plaques,” Nature, 40:116-117 (1999).
Stein et al., “Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways,” The Journal of Neuroscience, 22(17):7380-7388 (2002).
Stern et al., “Antibodies to the β-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood,” FEBS Letters, 264(1):43-47 (1990).
Stoute et al., “A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria”, N. Engl. J. Med., 336(2):86-91 (1997).
Strbak et al., “Passive Immunization and Hypothalamic Peptide Secretion”, Neuroendocrinology, 58:210-217 (1993).
Sturchler-Pierrat et al., “Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology,” PNAS, 94: 13287-13292 (1997).
Su et al., “Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage,” Brain Research, 818:105-107 (1999).
Suo et al., “Soluble Alzhelmers β-amyloid constricts the cerebral vasculature in vivo” Neuroscience Letters, 257:77-80 (1998).
Supplementary Partial European Search Report of Apr. 10, 2007 for European Application 04720353.4-1222.
Szendrei, et al., “The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments,” Int. J. Peptide Protein Res., 47:289-296 (1996).
Tabaton et al., “Soluble amyloid β-protein is a maker of Alzheimer amyloid in brain but not in cerebrospinal fluid,” Biochem. and Biophys. Res. Comm., 200(3):1598-1603 (1994).
Tal et al., “Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice,” Journal of Neuroscience Research, 71:286-290 (2003).
Tan et al., “Amyloidosis,” Histopathology, 25:403-414 (1994).
Tanaka et al., “NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats,” European J. Pharmacology, 352:135-142 (1998).
Tang et al., “Genetic immunization is a siple method for eliciting an immune response,” Nature, 356:152-154 (1992).
Teller et al., “Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome” Nature Medicine, 2(1):93-95 (1996).
Tennent et al., “Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis,” PNAS, 92:4299-4303 (1995).
Thorsett, E.D. et al., “Therapeutic approaches to Alzheimer's disease,” Curr. Op. in Chem. Biology, 4:377-382 (2000).
Tjernberg et al., “A molecular model for Alzheimer amyloid β-peptide fibril formation,” J. Biol. Chem., 274(18):12619-12625 (1999).
Tjernberg et al., “Arrest of β-amyloid fibril formation by a pentapeptide ligand,” J. Biol. Chem., 271:8545-8548 (1996).
Tjernberg, et al, “Controlling amyloid beta-peptide fibril formation with protease-stable ligands,” J. Biol Chem., 272(19):12601-12605 (1997).
Town et al., “Characterization of murine immunoglobulin G antibodies against human amyloid-β1-42” Neurosci. Lett, 307:101-104 (2001).
Travis, J., “Saving the Mind Faces High Hurdles,” Science, 309:731-734 (2005).
Trieb et al., “Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease,” Immunobiology, 191(2-3):114-115 Abstract C.37, (1994).
Tsuzuki et al., “Amyloid β protein in rat soleus in choroquine-induced myopthy using end-specific antibodies of Aβ40 and Aβ42: immunohistochemical evidence for amyloid β protein,” Neuroscience Letters, 2002:77-80 (1995).
Van Gool et al., “Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease,” Neuroscience Letters, 172:122-124 (1994).
Van Regenmortel et al, “D-peptides as immunogens and diagnostic reagents,” Curr. Opin. Biotechnol., 9(4):377-382 (1998).
Vanderstichele et al., “Standardization of Measurement of B-amyloid(1-42) in Cerebrospinal Fluid and Plasma:,” Int. J. Exp. Clin. Invest., 7(4):245-258 (2000).
Velazquez et al., “Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis,” Nature Medicine, 3(1):77-79 (1997).
Verbeek et al., “Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease,” Amer. Journ. Pathology, 144(1):104-116 (1994).
Verma et al., “Gene therapy—promises, problems and prospects,” Nature, 389:239-242 (1997).
Walker et al., “Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody,” J. Neuropath. Exp. Neurology, 53(4):377-383 (1994).
Wang et al., “The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging,” Experimental Neurology, 158:328-337 (1999).
Wang et al., “Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rate dentate gyrus,” Brain Research, 924:133-140 (2002).
Weiner et al., “Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens,” Annu. Rev. Immunol., 12:809-837 (1994).
Weissmann et al., “Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease,” Curr. Opin. Neurobiol., 7:695-700 (1997).
Weldon et al., “Neurotoxicity of Aβ Peptide: Confocal Imaging of Cellular Changes Induced by -Amyloid in Rat CNS In Vivo,” Society for Neuroscicence Abstracts, 22(Part 1) (1996).
Wells, J. A., “Additivity of Mutational Effects in Proteins,” Biochemistry, 29(37):8509-8517 (1990).
Wen, G.Y., “Alzheimer's Disease and Risk Factors,” J. Food Drug Analysis, 6(2):465-476 (1998).
Wengenack et al., “Targeting Alzheimer amyloid plaques in vivo,” Nature Biotech., 18:868-872 (2000).
Winblad et al., “Hints of a therapeutic Vaccine for Alzheimer's?” Neuron, 38:517-519 (2003).
Winter et al., “Humanized antibodies” Immunology Today, 14(6):243-246 (1996).
Wisconsin Alumni Research Foundation, “Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals”, U.S. Govt. Res. Develop. Rep., 70(24), 56 (1969).
Wisniewski et al., “Alzheimer's disease and soluble A beta,” Neurobiol. Aging, 15(2):143-52 (1994).
Wisniewski et al., “Therapeutics in Alzheimer's and Prion Diseases,” Biochemical Society Transactions, 30(4):574-587 (2002).
Whitcomb et al., “Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain,” Am J Pysiol Gastrointest Liver Physiol, 259:G687-G691 (1990).
Wong et al., “Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related,” PNAS, 82:8729-8732 (1985).
Wood et al., “Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease,” PNAS, 94: 1550-1555 (1997).
Wood et al., “Prolines and amyloidogenicily in fragments of the Alzheimer's peptide β/A4” Biochemistry, 34:724-730 (1995).
Wu et al., “Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella,” PNAS, 86:4726-4730 (1989).
Wu, et al., “Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor,” J. Clin. Invest., 100:1804-1812 (1997).
Wyeth, Annual Review 2005: Creating Value . . . Advancing Health (Feb. 27, 2006).
Xiang et al., “Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines,” Immunity, 2(2):129-135 Abstract (1995).
Xu et al., “Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease,” Mechanisms of Ageing and Development, 94:213-222 (1997).
Yamaguchi et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques, Acta Neuropathol., 95:217-222 (1998).
Yang et al., “Effects of Racemization on the Aggregational Properties of the Amyloid β-Peptide in Alzheimer's Disease,” abstract # 255 from American Chemical Society 214th National Meeting (1997).
Yankner et al., “Neurotrophic and Neurotoxic effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides,” Science, 250:279-282 (1990).
Younkin, “Amyloid β vaccination: reduced plaques and improved cognition,” Nature Medicine, 7:18-19 (2001).
Zlokovic et al., “Clearance of amyloid β-peptide from brain: transport or metabolism?,” Nature Medicine, 6(7):718-719 (2000).
* cited by examiner

Patent Family

The current document is not in a family.